WS #7916
The dominant narrative from the previous window—SpaceX IPO, IEA oil shock warning, and corporate catalysts—remains active, with new corroborating details. The SpaceX IPO filing is now widely covered by multiple sources (Ars Technica, TechCrunch, Bloomberg, SCMP), with the $75 billion raise and $1.7 trillion valuation confirmed. The IEA chief's warning that the current oil shock is more dramatic than 1973, 1979, and 2022 is reiterated, reinforcing the bearish macro backdrop. New signals include: IMAX exploring a sale (confirmed by Seeking Alpha and Benzinga), Conduent selling its public transit unit for $164M (stock jumped 12% after hours), and Biogen/Denali's Phase 2b Parkinson's trial failure (DNLI halted, BIIB negative). The IRGC Navy claims Strait of Hormuz remains closed, adding to geopolitical risk. Gold ticks higher on Iran uncertainty. The narrative arc is STABLE with respect to the prevailing themes, but the IMAX sale and Biogen/Denali trial failure add new sector-specific catalysts.
Key developments
- SpaceX files for IPO targeting $75B raise and $1.7T valuation
- IEA chief warns oil shock more dramatic than 1973, 1979, 2022
- IMAX exploring sale, shares pop
- Conduent sells public transit unit for $164M, shares jump 12% after hours
- Biogen/Denali Parkinson's trial fails, development discontinued
- IRGC Navy says Strait of Hormuz remains closed